Haisco Pharmaceutical Group Co., Ltd. is a high-risk pharmaceutical company in China specializing in drugs for liver disease. With a Risk Rating Score of 36.1, Haisco Pharmaceutical Group Co Ltd focuses on research, development, and sale of parenteral nutrition drugs, antibiotics, anesthetic agents, and more. Their products are trusted by top hospitals in China. ESG considerations play a crucial role in their operations.